• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Demyelinating Diseases - Pipeline Review, H2 2012 Product Image

Demyelinating Diseases - Pipeline Review, H2 2012

  • Published: December 2012
  • 87 pages
  • Global Markets Direct

Demyelinating Diseases – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Demyelinating Diseases - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Demyelinating Diseases, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Demyelinating Diseases. Demyelinating Diseases - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Demyelinating Diseases.
- A review of the Demyelinating Diseases products under development by companies READ MORE >

2
List of Tables 5
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Demyelinating Diseases Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Demyelinating Diseases 8
Demyelinating Diseases Therapeutics under Development by Companies 10
Demyelinating Diseases Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Demyelinating Diseases Therapeutics – Products under Development by Companies 16
Demyelinating Diseases Therapeutics – Products under Investigation by Universities/Institutes 17
Companies Involved in Demyelinating Diseases Therapeutics Development 18
Genzyme Corporation 18
F. Hoffmann-La Roche Ltd. 19
Biogen Idec Inc. 20
Sanofi-Aventis 21
Novartis AG 22
Elan Corporation, plc 23
Opexa Therapeutics, Inc. 24
Innate Therapeutics Limited 25
AB Science 26
Daval International Ltd. 27
Elan Pharmaceuticals, Inc 28
Demyelinating Diseases – Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Combination Products 30
Drug Profiles 31
teriflunomide - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
fingolimod hydrochloride - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
ocrelizumab - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
alemtuzumab - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
alemtuzumab - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Peginterferon beta-1a - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
natalizumab - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
imilecleucel-t - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
(R)-Lipoic acid - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
minocycline - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
masitinib - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
cyclophosphamide - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Aimspro - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
MIS-416 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
natalizumab SC - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
eculizumab - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
T Cell Vaccination - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Demyelinating Diseases Therapeutics – Drug Profile Updates 60
Demyelinating Diseases Therapeutics – Discontinued Products 77
Demyelinating Diseases – Product Development Milestones 78
Featured News & Press Releases 78
Nov 13, 2012: Opexa Receives Clinical Trial Approval From Health Canada For New T-Cell Therapy, Tcelna 78
Sep 12, 2012: Opexa Initiates Phase IIb Clinical Trial Of Tcelna In Patients With Secondary Progressive Multiple Sclerosis 79
Sep 12, 2012: Genzyme Receives FDA Approval For Aubagio For Treatment Of Relapsing Multiple Sclerosis 80
Aug 27, 2012: Genzyme Provides Update On US LEMTRADA Filing 81
Aug 23, 2012: Novartis In Partnership With Health Canada To Introduce Revised Product Monograph For Gilenya 81
Jun 12, 2012: Genzyme Submits Applications To FDA And EMA For Approval Of LEMTRADA For Multiple Sclerosis 82
Jun 01, 2012: Genzyme Reports Positive Top-Line Pivotal Phase III Trial Results For AUBAGIO In Relapsing Multiple Sclerosis 83
May 21, 2012: Opexa Announces Tcelna As New Brand Name For MS Therapy 84
Sep 11, 2009: Sanofi Oral MS Drug Teriflunomide Reduces Cerebral Lesions In Phase II Trial 84
Feb 12, 2009: FDA Grants Fast Track Status To Oral Laquinimod For Multiple Sclerosis. 85
Appendix 86
Methodology 86
Coverage 86
Secondary Research 86
Primary Research 86
Expert Panel Validation 86
Contact Us 87
Disclaimer 87

List of Tables
Number of Products Under Development for Demyelinating Diseases, H2 2012 8
Products under Development for Demyelinating Diseases – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Late Stage Development, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Comparative Analysis by Early Clinical Stage Development, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 17
Genzyme Corporation, H2 2012 18
F. Hoffmann-La Roche Ltd., H2 2012 19
Biogen Idec Inc., H2 2012 20
Sanofi-Aventis, H2 2012 21
Novartis AG, H2 2012 22
Elan Corporation, plc, H2 2012 23
Opexa Therapeutics, Inc., H2 2012 24
Innate Therapeutics Limited, H2 2012 25
AB Science, H2 2012 26
Daval International Ltd., H2 2012 27
Elan Pharmaceuticals, Inc, H2 2012 28
Assessment by Monotherapy Products, H2 2012 29
Assessment by Combination Products, H2 2012 30
Demyelinating Diseases Therapeutics – Drug Profile Updates 60
Demyelinating Diseases Therapeutics – Discontinued Products 77

List of Figures
Number of Products under Development for Demyelinating Diseases, H2 2012 8
Products under Development for Demyelinating Diseases – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 12
Late Stage Products, H2 2012 13
Mid Clinical Stage Products, H2 2012 14
Early Clinical Stage Products, H2 2012 15
Assessment by Monotherapy Products, H2 2012 29
Assessment by Combination Products, H2 2012 30

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos